Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx

Cancer

Volumn 95, Issue 1, 2002, Pages 90-97

  De Stefani, Antonella ^a,b   Forni, Guido ^c   Ragona, Riccardo ^a   Cavallo, Giovanni ^a   Bussi, Mario ^a   Usai, Antonio ^a,b   Badellino, Fausto ^d   Cortesina, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Perilymphatic; Recombinant interleukin 2; Recurrence; Squamous cell carcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OROPHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; HUMANS; INTERLEUKIN-2; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 0036645001     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10654     Document Type: Article

References (26)

1. Cytokines, tumor cell death and immunogenicity: A question of choice
2. Lymphokine-activated tumor inhibition in vivo. The local administration of interleukin-2 triggers non-reactive lymphocytes from tumor-bearing mice to inhibit tumor growth
3. Effects of local cytokine therapy
4. Treatment of recurrent squamous cell carcinoma of head and neck with low doses of interleukin-2 (IL-2) injected perilymphatically
5. Temporary regression of recurrent squamous cell carcinoma of the head and neck achieved with low but not with high dose of recombinant interleukin-2 injected perilymphatically
6. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma
7. Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant Interleukin-2. A pathological and immunophenotypical study
8. Immune complexes, serum proteins, cell-mediated immunity and immune regulation in patients with squamous cell carcinoma of the head and neck
9. The use of nitrogen mustard in the palliative treatment of carcinoma
10. Cervical lymphography: Difficulties and advantages
11. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors
12. Evaluation of simple size and power of analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification
13. Cancer statistics 1994
14. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck
15. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12
16. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2. Clinical and pathologic correlations
17. Local continuous high-dose interleukin-2: New therapeutic model for treatment of advanced bladder carcinoma
18. Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumor in situ
19. The immunology of head and neck cancer: Prospects for immunotherapy